Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer assays. The key finding is that EndoPredict test was more than twice as cost effective as Oncotype DX®. Breast cancer is the most common cancer in women worldwide.
“Payers would benefit from understanding the financial implications of using gene expression tests to determine recurrence risk in women with early-stage breast cancer,” said Malek B. Hannouf, Ph.D., lead investigator, London Health Sciences Centre, Ontario, Canada. “Our study provides firm evidence validating the economic value of incorporating EndoPredict into patient care.”
This study examined the cost effectiveness of incorporating gene expression testing into standard practice using data from the Anastrozole or Tamoxifen Alone or Combined (ATAC) clinical trial and cost data from the London Regional Cancer Program and other Canadian sources. The analysis evaluated three genetic tests compared to the clinicopathological (CP) features traditionally used to guide adjuvant treatment decisions. The primary endpoint was quality adjusted life years (QALY), which is a measure of the value of health outcomes. The results show that compared to the CP predictors alone-based strategy, EndoPredict was the single most cost-effective genetic test ($36,274/QALY) and was more than twice as cost effective as the market leading Oncotype DX test ($74,911/QALY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.